Research & Literature

Updates to the management of chronic lymphocytic leukemia.

Wierda WG

Journal of the National Comprehensive Cancer Network : JNCCN 2015; (13(5 Suppl)):662-5 doi:10.6004/jnccn.2015.0197.

Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

Strati P, Shanafelt TD

Blood 2015; (126(4)):454-62 doi:10.1182/blood-2015-02-585059.

Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada.

Huang SJ, Gillan TL, Gerrie AS, et al.

Genes, chromosomes & cancer 2016; (55(1)):16-24 doi:10.1002/gcc.22294.

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Fischer K, Bahlo J, Fink AM, et al.

Blood 2016; (127(2)):208-15 doi:10.1182/blood-2015-06-651125.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Thompson PA, Tam CS, O'Brien SM, et al.

Blood 2016; (127(3)):303-9 doi:10.1182/blood-2015-09-667675.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Roberts AW, Davids MS, Pagel JM, et al.

The New England journal of medicine 2016; (374(4)):311-22 doi:10.1056/NEJMoa1513257.

Transformation in Low-grade B-cell Neoplasms.

Montgomery ND, Mathews SP

Surgical pathology clinics 2016; (9(1)):79-92.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Stilgenbauer S, Eichhorst B, Schetelig J, et al.

The Lancet. Oncology 2016; (17(6)):768-778 doi:10.1016/S1470-2045(16)30019-5.

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Eichhorst B, Fink AM, Bahlo J, et al.

The Lancet. Oncology 2016; (17(7)):928-942 doi:10.1016/S1470-2045(16)30051-1.

[Pathologic characteristics of bone marrow for 
CD5 positive small B cell lymphoma].

Peng S, Zhu F, You S, et al.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2016; (41(4)):374-9 doi:10.11817/j.issn.1672-7347.2016.04.006.

Richter transformation of CLL.

Jain N, Keating MJ

Expert review of hematology 2016; (9(8)):793-801 doi:10.1080/17474086.2016.1199948.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, et al.

The Lancet. Oncology 2017; (18(2)):230-240 doi:10.1016/S1470-2045(17)30012-8.

Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Sun Y, Wang SA, Sun T

Cytometry. Part B, Clinical cytometry 2018; (94(1)):148-150 doi:10.1002/cyto.b.21512.

Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.

Hallek M

American journal of hematology 2017; (92(9)):946-965 doi:10.1002/ajh.24826.

An unusual presentation of chronic lymphocytic leukemia.

Atwal D, Raval M, Firwana B, et al.

Avicenna journal of medicine 2017; (7(3)):133-136 doi:10.4103/ajm.AJM_171_16.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, et al.

Cytometry. Part B, Clinical cytometry 2018; (94(1)):121-128 doi:10.1002/cyto.b.21595.

Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.

Khan M, Siddiqi R, Thompson PA

Annals of hematology 2018; (97(1)):1-15 doi:10.1007/s00277-017-3149-9.

Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms.

Starostka D, Kriegova E, Kudelka M, et al.

Cytometry. Part B, Clinical cytometry 2018; (94(4)):576-587 doi:10.1002/cyto.b.21607.

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

Kadri S, Lee J, Fitzpatrick C, et al.

Blood advances 2017; (1(12)):715-727 doi:10.1182/bloodadvances.2016003632.

Frontline Therapy of CLL: Evolving Treatment Paradigm.

Boddy CS, Ma S

Current hematologic malignancy reports 2018; (13(2)):69-77 doi:10.1007/s11899-018-0438-x.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, et al.

Blood 2018; (131(25)):2745-2760 doi:10.1182/blood-2017-09-806398.

Biology and treatment of Richter syndrome.

Rossi D, Spina V, Gaidano G

Blood 2018; (131(25)):2761-2772 doi:10.1182/blood-2018-01-791376.

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.

Teh BW, Tam CS, Handunnetti S, et al.

Blood reviews 2018; (32(6)):499-507 doi:10.1016/j.blre.2018.04.007.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(19)):1973-1980 doi:10.1200/JCO.2017.76.6840.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, et al.

Haematologica 2018; (103(9)):1511-1517 doi:10.3324/haematol.2018.193615.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, et al.

Blood 2019; (133(26)):2765-2775 doi:10.1182/blood-2019-01-896290.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(14)):4264-4270 doi:10.1158/1078-0432.CCR-19-0361.

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.

Hallek M

American journal of hematology 2019; (94(11)):1266-1287 doi:10.1002/ajh.25595.

Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia.

Sorigue M, Magnano L, Miljkovic MD, et al.

Cytometry. Part B, Clinical cytometry 2020; (98(5)):441-448 doi:10.1002/cyto.b.21849.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

Wierda WG, Byrd JC, Abramson JS, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(2)):185-217.

Stage IV Small Lymphocytic Lymphoma Presenting with Unilateral Vision Loss.

Le C, Jacob A, Iyengar D, et al.

Case reports in oncological medicine 2020; (2020()):3752409 doi:10.1155/2020/3752409.

Precision Medicine Management of Chronic Lymphocytic Leukemia.

Moia R, Patriarca A, Schipani M, et al.

Cancers 2020; (12(3)) doi:10.3390/cancers12030642.

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.

Tausch E, Schneider C, Robrecht S, et al.

Blood 2020; (135(26)):2402-2412 doi:10.1182/blood.2019004492.

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.

Byrd JC, Furman RR, Coutre SE, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(15)):3918-3927 doi:10.1158/1078-0432.CCR-19-2856.

Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.

Yoshino T, Tanaka T, Sato Y

Journal of clinical and experimental hematopathology : JCEH 2020; (60(4)):124-129 doi:10.3960/jslrt.19041.

Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?

Suzumiya J, Takizawa J

International journal of hematology 2020; (111(5)):642-656 doi:10.1007/s12185-020-02867-0.

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

Al-Sawaf O, Zhang C, Tandon M, et al.

The Lancet. Oncology 2020; (21(9)):1188-1200 doi:10.1016/S1470-2045(20)30443-5.

Ulcerated cutaneous Richter syndrome.

De Mello RB, Do Vale ECS

Dermatology online journal 2020; (26(9)).

The Pattern of Use of PET/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia.

Hod K, Tova Y, Gold O, et al.

Clinical lymphoma, myeloma & leukemia 2021; (21(8)):558-563 doi:10.1016/j.clml.2021.04.003.

Life-Threatening Fungal Infection in Richter Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Case Report and Brief Review of Literature.

Baral B, Ahuja K, Chhabra N, et al.

Cureus 2021; (13(6)):e15924 doi:10.7759/cureus.15924.

Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.

Elnair R, Ellithi M, Kallam A, et al.

Annals of hematology 2021; (100(10)):2513-2519 doi:10.1007/s00277-021-04603-y.

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

Byrd JC, Hillmen P, Ghia P, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(31)):3441-3452 doi:10.1200/JCO.21.01210.

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.

Brown JR, Byrd JC, Ghia P, et al.

Haematologica 2022; (107(6)):1335-1346 doi:10.3324/haematol.2021.278901.

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Hallek M, Al-Sawaf O

American journal of hematology 2021; (96(12)):1679-1705 doi:10.1002/ajh.26367.

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.

Tam CS, Dimopoulos M, Garcia-Sanz R, et al.

Blood advances 2022; (6(4)):1296-1308 doi:10.1182/bloodadvances.2021005621.

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.

Langerbeins P, Zhang C, Robrecht S, et al.

Blood 2022; (139(2)):177-187 doi:10.1182/blood.2021010845.

Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall.

Qiu L, Xu J, Tang G, et al.

Human pathology 2022; (119()):59-68 doi:10.1016/j.humpath.2021.11.001.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t(11;14)(q13;q32)/CCND1-IGH: A Rare Variant Of Richter Transformation to Mantle Cell Lymphoma.

Zhao Y, McCracken J, Rehder C, Wang E

Clinical lymphoma, myeloma & leukemia 2022; (22(5)):e310-e313 doi:10.1016/j.clml.2021.10.017.

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.

O'Brien SM, Brown JR, Byrd JC, et al.

Frontiers in oncology 2021; (11()):720704 doi:10.3389/fonc.2021.720704.

Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.

Allan JN, Shanafelt T, Wiestner A, et al.

British journal of haematology 2022; (196(4)):947-953 doi:10.1111/bjh.17984.

Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas.

Rangan A, Reinig E, McPhail ED, Rech KL

Human pathology 2022; (121()):29-35 doi:10.1016/j.humpath.2022.01.001.

Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.

Almasri M, Amer M, Ghanej J, et al.

Life (Basel, Switzerland) 2022; (12(2)) doi:10.3390/life12020283.

New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.

Iskierka-Jażdżewska E, Obracaj A, Urbaniak M, Robak T

Current treatment options in oncology 2022; (23(6)):775-795 doi:10.1007/s11864-022-00974-0.

Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.

Hanna KS, Fijalka A, Watson I, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022; (28(8)):1869-1884 doi:10.1177/10781552221103820.

International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.

Awan FT, Addison D, Alfraih F, et al.

Blood advances 2022; (6(18)):5516-5525 doi:10.1182/bloodadvances.2022007938.

Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials.

Jiang D, Song Z, Hu Y, et al.

Expert review of clinical pharmacology 2022; (15(8)):987-996 doi:10.1080/17512433.2022.2106968.

Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.

Xu W, Yang S, Tam CS, et al.

Advances in therapy 2022; (39(9)):4250-4265 doi:10.1007/s12325-022-02238-7.

An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.

Broadway-Duren J

Journal of the advanced practitioner in oncology 2022; (13(5)):535-538 doi:10.6004/jadpro.2022.13.5.7.

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.

St-Pierre F, Ma S

Blood and lymphatic cancer : targets and therapy 2022; (12()):81-98 doi:10.2147/BLCTT.S326627.

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.

Shadman M

JAMA 2023; (329(11)):918-932 doi:10.1001/jama.2023.1946.

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.

Seymour JF, Byrd JC, Ghia P, et al.

Blood 2023; (142(8)):687-699 doi:10.1182/blood.2022018818.

How I Manage Chronic Lymphocytic Leukemia.

Nasnas P, Cerchione C, Musuraca G, et al.

Hematology reports 2023; (15(3)):454-464 doi:10.3390/hematolrep15030047.

Prognostic Markers in the Era of Targeted Therapies.

Kang S, Ahn IE

Acta haematologica 2024; (147(1)):33-46 doi:10.1159/000533704.

Atypical Chronic Lymphocytic Leukemia-The Current Status.

Robak T, Krawczyńska A, Cebula-Obrzut B, et al.

Cancers 2023; (15(18)) doi:10.3390/cancers15184427.

Association of Cytogenetics Aberrations and IGHV Mutations with Outcome in Chronic Lymphocytic Leukemia Patients in a Real-World Clinical Setting.

Muñoz-Novas C, González-Gascón-Y-Marín I, Figueroa I, et al.

Global medical genetics 2024; (11(1)):59-68 doi:10.1055/s-0044-1779668.

Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care.

Anderson MA, Walewska R, Hackett F, et al.

Cancers 2024; (16(5)) doi:10.3390/cancers16050980.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Wierda WG, Brown J, Abramson JS, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(3)):175-204 doi:10.6004/jnccn.2024.0018.

Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors.

Mauro FR, Frustaci AM, Visentin A, et al.

Critical reviews in oncology/hematology 2024; (201()):104408 doi:10.1016/j.critrevonc.2024.104408.

IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence.

Soumerai JD, Yousif Z, Gift T, et al.

Blood advances 2024; (8(16)):4239-4249 doi:10.1182/bloodadvances.2024013073.

Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.

Robak T, Puła A, Braun M, Robak E

Annals of hematology 2024; (103(9)):3369-3383 doi:10.1007/s00277-024-05854-1.

Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center.

Narang M, Horn C, Lee E

Clinical Medicine Insights. Oncology 2024; (18()):11795549241275665 doi:10.1177/11795549241275665.

"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): unraveling the biological gray zone of CLL/SLL in the era of novel therapies.

Vadasz B, Zak T, Aldinger J, et al.

Virchows Archiv : an international journal of pathology 2025; (486(4)):739-750 doi:10.1007/s00428-024-03920-7.

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Langerbeins P, Robrecht S, Nieper P, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(4)):392-402 doi:10.1200/JCO.24.00975.

Risk-stratification in frontline CLL therapy: standard of care.

Tausch E, Schneider C, Stilgenbauer S

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):457-466 doi:10.1182/hematology.2024000656.

[Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)].

Medina Á, Muntañola A, Crespo M, et al.

Medicina clinica 2025; (164(6)):305-305.e17 doi:10.1016/j.medcli.2024.10.018.

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.

Hallek M

American journal of hematology 2025; (100(3)):450-480 doi:10.1002/ajh.27546.

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

Brown JR, Seymour JF, Jurczak W, et al.

The New England journal of medicine 2025; (392(8)):748-762 doi:10.1056/NEJMoa2409804.

The Heterogeneity of 13q Deletions in Chronic Lymphocytic Leukemia: Diagnostic Challenges and Clinical Implications.

Xia C, Liu G, Liu J, et al.

Genes 2025; (16(3)) doi:10.3390/genes16030252.

When and How Long to Treat Chronic Lymphocytic Leukemia?

Niemann CU, Varghese A, Munir T, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e473656 doi:10.1200/EDBK-25-473656.

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.

Shadman M, Munir T, Ma S, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(21)):2409-2417 doi:10.1200/JCO-25-00758.

Chronic lymphocytic leukemia: criteria for first-line therapeutic choice-an opinion paper.

Carda J, Martins Â, Alves D, Gomes M

Medical oncology (Northwood, London, England) 2025; (42(11)):493 doi:10.1007/s12032-025-03046-z.

Severe Hypercalcemia in a Patient with Chronic Lymphocytic Leukemia following Treatment Disruption.

Al-Bitar A, Al Bidewi Y, Alsawaf K, et al.

Case reports in oncology 2025; (18(1)):1256-1261 doi:10.1159/000548015.

Tonsillar Hypertrophy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Mini-Review.

Al-Shibly R, Ali EA, Qasem NM, et al.

Cureus 2025; (17(11)):e96963 doi:10.7759/cureus.96963.

Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients.

Dingli D, De Nigris E, Leng S, et al.

Future oncology (London, England) 2026; (22(1)):71-82 doi:10.1080/14796694.2025.2600913.

First-line treatment for CLL in the era of targeted therapy.

Davids MS, Stilgenbauer S, Tam CS

Blood cancer journal 2026; (16(1)):19 doi:10.1038/s41408-025-01434-2.

Plasmablastic Transformation of CLL/SLL: The Role of Early NGS Diagnosis and Targeted Multimodal Therapy.

Filipović J, Milošević S, Terzić T, et al.

Diagnostics (Basel, Switzerland) 2026; (16(5)) doi:10.3390/diagnostics16050702.

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.

Ghia P, Brown JR, Shadman M, Wendtner CM

Oncology and therapy 2026; (14(2)):519-541 doi:10.1007/s40487-026-00443-w.

To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.

Martino EA, Caserta S, Vigna E, et al.

European journal of haematology 2026; (117(4)):750-766 doi:10.1111/ejh.70219.

Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.

Fang CY, MacFarlane AW, Fung HCH, et al.

Cancer medicine 2026; (15(5)):e71903 doi:10.1002/cam4.71903.

Living with chronic lymphocytic leukaemia: A qualitative evidence synthesis of patient, caregiver and practitioner perspectives.

Hackett F, O'Donnell C, Galvin R, et al.

European journal of oncology nursing : the official journal of European Oncology Nursing Society 2026; (83()):103206 doi:10.1016/j.ejon.2026.103206.

Safety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia.

Ailawadhi S, Omercikoglu E, Paulus A, et al.

Drug safety 2026; (49(10)):1135-1159 doi:10.1007/s40264-026-01678-2.